(Total Views: 339)
Posted On: 10/23/2018 12:23:02 PM
Post# of 72446
I wish people would just read the freaking PR's and they wouldn't need to make such stupid statements. My buddy Mr. Soft Basher Frrol was questioning whether the results from Kevetrin P2a were sufficient to move forward. Well obviously they were if we are going to pill formulation, but if he had read the PR from September 2017 he would have his answer and not need to put doubts out there.
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
This is EXACTLY what IPIX is doing!!!!!!
"What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
This is EXACTLY what IPIX is doing!!!!!!
(7)
(0)
